[1] HJFELDT JW,AGGER K,HELIN K.Histone lysine demethylases as targets for anticancer therapy[J].Nat Rev Drug Discov,2013,12(12):917-930.
[2] DEFEO-JONES D,HUANG PS,JONES RE,et al.Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product[J].Nature,1991,352(6332):251-254.
[3] CHAN SW,HONG W.Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription[J].J Biol Chem,2001,276(30):28402-28412.
[4] HORTON JR,LIU X,GALE M,et al.Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds[J].Cell Chem Biol,2016,23(7):769-781.
[5] LONGBOTHAM JE,CHIO CM,DHARMARAJAN V,et al.Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling[J].Nat Commun,2019,10(1):94.
[6] PETRONIKOLOU N,LONGBOTHAM JE,FUJIMORI DG.Extended recognition of the histone H3 tail by histone demethylase KDM5A[J].Biochemistry,2020,59(5):647-651.
[7] BESHIRI ML,ISLAM A,DEWAAL DC,et al.Genome-wide analysis using ChIP to identify isoform-specific gene targets[J].Jove-Journal of Visualized Experiments,2010,41:e2101.
[8] HAN X,TAN Q,YANG S,et al.Comprehensive profiling of gene copy number alterations predicts patient prognosis in resected stages I-III lung adenocarcinoma[J].Front Oncol,2019,9:556.
[9] DAHL JA,JUNG I,AANES H,et al.Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition[J].Nature,2016,537(7621):548-552.
[10] BENEVOLENSKAYA EV,MURRAY HL,BRANTON P,et al.Binding of pRB to the PHD protein RBP2 promotes cellular differentiation[J].Mol Cell,2005,18(6):623-635.
[11] BRIER AB,LOFT A,MADSEN JGS,et al.The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation[J].Nucleic Acids Res,2017,45(4):1743-1759.
[12] ZARGAR ZU,KIMIDI MR,TYAGI S.Dynamic site-specific recruitment of RBP2 by pocket protein p130 modulates H3K4 methylation on E2F-responsive promoters[J].Nucleic Acids Res,2018,46(1):174-188.
[13] KUMAR A,KUMARI N,SHARMA U,et al.Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma:prognostic and therapeutic implications[J].Sci Rep,2019,9(1):8189.
[14] GUO L,GUO YY,LI BY,et al.Histone demethylase KDM5A is transactivated by the transcription factor C/EBPβ and promotes preadipocyte differentiation by inhibiting Wnt/β-catenin signaling[J].J Biol Chem,2019,294(24):9642-9654.
[15] KONG SY,KIM W,LEE HR,et al.The histone demethylase KDM5A is required for the repression of astrocytogenesis and regulated by the translational machinery in neural progenitor cells[J].Faseb J,2018,32(2):1108-1119.
[16] VRALJAI R,ISLAM AB,BESHIRI ML,et al.Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells[J].Genes Dev,2015,29(17):1817-1834.
[17] PENG D,LIN B,XIE M,et al.Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor[J].Cell Death Discov,2021,7(1):9.
[18] WU H,XU L,HU X.KDM5A regulates the growth and gefitinib drug resistance against human lung adenocarcinoma cells[J].Biotech,2022,12(4):97.
[19] LI L,WANG L,SONG P,et al.Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis[J].Mol Cancer,2014,13:81.
[20] MA YS,WU TM,QIAN B,et al.KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation[J].J Cell Mol Med,2021,25(8):4040-4052.
[21] HU D,JABLONOWSKI C,CHENG PH,et al.KDM5A regulates a translational program that controls p53 protein expression[J].iScience,2018,9:84-100.
[22] CUI J,QUAN M,XIE D,et al.A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism[J].Oncogene,2020,39(5):1140-1151.
[23] SHOKRI G,DOUDI S,FATHI-ROUDSARI M,et al.Targeting histone demethylases KDM5A and KDM5B in AML cancer cells:A comparative view[J].Leuk Res,2018,68:105-111.
[24] YOU JH,LEE J,ROH JL.Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition[J].Cancer Lett,2021,507:40-54.
[25] YIN X,ZHOU M,FU Y,et al.Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade[J].Cell Signal,2019,63:109360.
[26] DAI B,HUANG H,GUAN F,et al.Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1[J].Biomed Pharmacother,2018,99:72-80.
[27] LI H,PENG C,ZHU C,et al.Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner[J].Clin Epigenetics,2021,13(1):18.
[28] REN F,SHRESTHA C,SHI H,et al.Targeting of KDM5A by miR-421 in human ovarian cancer suppresses the progression of ovarian cancer cells[J].Onco Targets Ther,2020,13:9419-9428.
[29] DU C,LYU C,FENG Y,et al.Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression[J].J Exp Clin Cancer Res,2020,39(1):223.
[30] FENG T,WANG Y,LANG Y,et al.KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance[J].Mol Med Rep,2017,16(3):3573-3580.
[31] LIU J,ZHAO H,ZHANG Q,et al.Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway[J].Exp Cell Res,2020,396(1):112277.
[32] MCCANN TS,PARRISH JK,HSIEH J,et al.KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1,and promote growth and metastatic properties in Ewing sarcoma[J].Oncotarget,2020,11(43):3818-3831.
[33] SHARMA SV,LEE DY,LI B,et al.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J].Cell,2010,141(1):69-80.
[34] HOU J,WU J,DOMBKOWSKI A,et al.Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer[J].Am J Transl Res,2012,4(3):247-256.
[35] HINOHARA K,WU HJ,VIGNEAU S,et al.KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance[J].Cancer Cell,2018,34(6):939-953.
[36] GONG F,CLOUAIRE T,AGUIRREBENGOA M,et al.Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair[J].J Cell Biol,2017,216(7):1959-1974.
[37] XU L,WU H,HU X.Histone demethylase KDM5A enhances cell proliferation,induces EMT in lung adenocarcinoma cells,and have a strong causal association with paclitaxel resistance[J].Acta Biochim Pol,2021,68(4):593-602.
[38] BURKHART DL,SAGE J.Cellular mechanisms of tumour suppression by the retinoblastoma gene[J].Nat Rev Cancer,2008,8(9):671-682.
[39] SEQUIST LV,WALTMAN BA,DIAS-SANTAGATA D,et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med,2011,3(75):75ra26.
[40] TAN HL,SOOD A,RAHIMI HA,et al.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma[J].Clin Cancer Res,2014,20(4):890-903.
[41] MCBRAYER SK,OLENCHOCK BA,DINATALE GJ,et al.Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase[J].Proc Natl Acad Sci USA,2018,115(16):e3741-e3748.
[42] HAM J,LEE S,LEE H,et al.Genome-wide methylation analysis identifies NOX4 and KDM5A as key regulators in inhibiting breast cancer cell proliferation by ginsenoside Rg3[J].Am J Chin Med,2018,46(6):1333-1355.
[43] OSER MG,SABET AH,GAO W,et al.The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis[J].Genes Dev,2019,33(23-24):1718-1738.
[44] HORTON JR,WOODCOCK CB,CHEN Q,et al.Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A[J].J Med Chem,2018,61(23):10588-10601.
[45] HORTON JR,LIU X,WU L,et al.Insights into the action of inhibitor enantiomers against histone lysine demethylase 5A[J].J Med Chem,2018,61(7):3193-3208.
[46] TAN SQ,GENG X,LIU JH,et al.Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1alpha and VEGF via inhibition of RBP2 and PKM2[J].BMC Complement Altern Med,2017,17(1):365.
[47] HORTON JR,ENGSTROM A,ZOELLER EL,et al.Characterization of a linked jumonji domain of the KDM5/JARID1 family of histone H3 lysine 4 demethylases[J].J Biol Chem,2016,291(6):2631-2646.
[48] MAR BG,CHU SH,KAHN JD,et al.SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia[J].Blood,2017,130(24):2631-2641.
[49] WANG L,CHANG J,VARGHESE D,et al.A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth[J].Nat Commun,2013,4:2035.
[50] GALE M,SAYEGH J,CAO J,et al.Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance[J].Oncotarget,2016,7(26):39931-39944.
[51] WU X,FANG Z,YANG B,et al.Discovery of KDM5A inhibitors:Homology modeling,virtual screening and structure-activity relationship analysis[J].Bioorg Med Chem Lett,2016,26(9):2284-2288.
[52] NIE Z,SHI L,LAI C,et al.Structure-based design and discovery of potent and selective KDM5 inhibitors[J].Bioorg Med Chem Lett,2018,28(9):1490-1494.
[53] DABIRI Y,GAMA-BRAMBILA RA,TASKOVA K,et al.Imidazopyridines as potent KDM5 demethylase inhibitors promoting reprogramming efficiency of human iPSCs[J].iScience,2019,12:168-181.
[54] MITSUI E,YOSHIDA S,SHINODA Y,et al.Identification of ryuvidine as a KDM5A inhibitor[J].Sci Rep,2019,9(1):9952.
[55] JAIKHAN P,BURANRAT B,ITOH Y,et al.Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors[J].Bioorg Med Chem Lett,2019,29(10):1173-1176.
[56] MIYAKE Y,ITOH Y,HATANAKA A,et al.Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy[J].Bioorg Med Chem,2019,27(6):1119-1129.
[57] LIU Y,YU Y,ZHANG J,et al.The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice[J].Life Sci,2019,239:116868.
[58] WANG L,GAO Y,ZHANG G,et al.Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade[J].Sci Transl Med,2020,12:2282.
[59] YANG GJ,WANG W,MOK SWF,et al.Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy[J].Angew Chem Int Ed Engl,2018,57(40):13091-13095.
[60] YANG GJ,KO CN,ZHONG HJ,et al.Structure-based discovery of a selective KDM5A inhibitor that exhibits anti-cancer activity via inducing cell cycle arrest and senescence in breast cancer cell lines[J].Cancers (Basel),2019,11(1):92.